Item(by='mejiaoneto', descendants=None, kids=None, score=None, time=1602882958, title=None, item_type='comment', url=None, parent=24804918, text='Thank you for your thoughts and question.<p>There has been a recent wave of intratumoral approaches particularly for immunooncology (e.g. TLR, Sting, oncolytic viruses) and there are manuscripts in the scientific literature about the technical challenges and possibilities (<a href="https:&#x2F;&#x2F;jamanetwork.com&#x2F;journals&#x2F;jamanetworkopen&#x2F;fullarticle&#x2F;2768765" rel="nofollow">https:&#x2F;&#x2F;jamanetwork.com&#x2F;journals&#x2F;jamanetworkopen&#x2F;fullarticle...</a>).<p>So, to your question, yes it is specialized, but not particularly difficult. We have taken great care to leverage the learnings of those experts to minimize the challenges of interpatient variability.<p>But we will only know for sure if our efforts where sufficient once the human clinical data comes back. For now I can say that our preclinical studies are highly encouraging.')